awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q42015329-B222A9D6-41FA-4897-8770-D3E5FE2506A0
Q42015329-B222A9D6-41FA-4897-8770-D3E5FE2506A0
BestRank
Statement
http://www.wikidata.org/entity/statement/Q42015329-B222A9D6-41FA-4897-8770-D3E5FE2506A0
Second European post-chicago melanoma meeting 2012.
P2860
Q42015329-B222A9D6-41FA-4897-8770-D3E5FE2506A0
BestRank
Statement
http://www.wikidata.org/entity/statement/Q42015329-B222A9D6-41FA-4897-8770-D3E5FE2506A0
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
8de9d8ddba5a4f4d554f2f222782bb530c019be0
P2860
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.